盈利预测修正
Search documents
AutoZone (AZO) Beats Q2 Earnings Estimates
ZACKS· 2026-03-03 14:05
Core Insights - AutoZone reported quarterly earnings of $27.63 per share, exceeding the Zacks Consensus Estimate of $27.1 per share, but down from $28.29 per share a year ago, resulting in an earnings surprise of +1.94% [1] - The company generated revenues of $4.27 billion for the quarter, missing the Zacks Consensus Estimate by 0.82%, compared to $3.95 billion in the same quarter last year [2] - AutoZone's stock has increased by approximately 14.5% year-to-date, significantly outperforming the S&P 500's gain of 0.5% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $36.30, with expected revenues of $4.83 billion, and for the current fiscal year, the EPS estimate is $148.80 on revenues of $20.48 billion [7] - The trend of earnings estimate revisions for AutoZone was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Automotive - Retail and Wholesale - Parts industry, to which AutoZone belongs, is currently ranked in the bottom 20% of over 250 Zacks industries, suggesting potential challenges ahead [8]
Wall Street Analysts Believe BioLife Solutions (BLFS) Could Rally 35%: Here's is How to Trade
ZACKS· 2026-03-02 15:56
Shares of BioLife Solutions, Inc. (BLFS) have gained 11% over the past four weeks to close the last trading session at $24.2, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $32.67 indicates a potential upside of 35%.The mean estimate comprises nine short-term price targets with a standard deviation of $1. While the lowest estimate of $31.00 indicates a 28.1% increase from the c ...
Wall Street Analysts Believe HCI Group (HCI) Could Rally 31.32%: Here's is How to Trade
ZACKS· 2026-03-02 15:56
Shares of HCI Group (HCI) have gained 11.2% over the past four weeks to close the last trading session at $176.42, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $231.67 indicates a potential upside of 31.3%.The average comprises three short-term price targets ranging from a low of $205.00 to a high of $255.00, with a standard deviation of $25.17. While the lowest estimate indi ...
Wall Street Analysts Believe Slide Insurance Holdings, Inc. (SLDE) Could Rally 28.42%: Here's is How to Trade
ZACKS· 2026-03-02 15:56
Shares of Slide Insurance Holdings, Inc. (SLDE) have gained 10.3% over the past four weeks to close the last trading session at $19, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $24.4 indicates a potential upside of 28.4%.The mean estimate comprises five short-term price targets with a standard deviation of $2.88. While the lowest estimate of $22.00 indicates a 15.8% increase ...
Wall Street Analysts See a 29.65% Upside in Aecom (ACM): Can the Stock Really Move This High?
ZACKS· 2026-02-27 15:55
Aecom Technology (ACM) closed the last trading session at $99.56, gaining 2.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $129.08 indicates a 29.7% upside potential.The mean estimate comprises 12 short-term price targets with a standard deviation of $12.09. While the lowest estimate of $110.00 indicates a 10.5% increase from the current price level, the most optimistic analyst ...
Wall Street Analysts Think DAVE INC (DAVE) Could Surge 56.04%: Read This Before Placing a Bet
ZACKS· 2026-02-27 15:55
Dave Inc. (DAVE) closed the last trading session at $192.33, gaining 12.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $300.11 indicates a 56% upside potential.The mean estimate comprises nine short-term price targets with a standard deviation of $31.79. While the lowest estimate of $250.00 indicates a 30% increase from the current price level, the most optimistic analyst expec ...
Autodesk (ADSK) Surpasses Q4 Earnings and Revenue Estimates
ZACKS· 2026-02-26 23:21
Core Viewpoint - Autodesk reported quarterly earnings of $2.85 per share, exceeding the Zacks Consensus Estimate of $2.63 per share, and showing an increase from $2.29 per share a year ago, representing an earnings surprise of +8.33% [1] Financial Performance - The company achieved revenues of $1.96 billion for the quarter ended January 2026, surpassing the Zacks Consensus Estimate by 2.48%, and up from $1.64 billion year-over-year [2] - Over the last four quarters, Autodesk has consistently surpassed consensus EPS estimates and revenue estimates [2] Stock Performance and Outlook - Autodesk shares have declined approximately 24.1% since the beginning of the year, contrasting with the S&P 500's gain of 1.5% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the sustainability of the recent earnings numbers [3][4] Earnings Estimates - The current consensus EPS estimate for the upcoming quarter is $2.57, with expected revenues of $1.84 billion, and for the current fiscal year, the estimate is $11.48 on revenues of $7.92 billion [7] - The trend of estimate revisions for Autodesk was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Internet - Software industry, to which Autodesk belongs, is currently ranked in the top 36% of over 250 Zacks industries, suggesting that stocks in the top half of the Zacks-ranked industries tend to outperform those in the bottom half by more than 2 to 1 [8]
BioCryst Pharmaceuticals (BCRX) Q4 Earnings and Revenues Surpass Estimates
ZACKS· 2026-02-26 18:16
BioCryst Pharmaceuticals (BCRX) came out with quarterly earnings of $1.12 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to a loss of $0.13 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +1,623.08%. A quarter ago, it was expected that this drugmaker would post earnings of $0.07 per share when it actually produced earnings of $0.06, delivering a surprise of -14.29%.Over the last four quarters ...
RE/MAX (RMAX) Moves to Buy: Rationale Behind the Upgrade
ZACKS· 2026-02-26 18:00
RE/MAX (RMAX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The power of a ...
Huron Consulting (HURN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
ZACKS· 2026-02-26 15:56
Shares of Huron Consulting (HURN) have been struggling lately and have lost 21.2% over the past four weeks. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the f ...